← back to search

Gerald B. Appel

NewYork–Presbyterian Hospital ·
Area of research
Nephrology · Rheumatology
Research interest
Research interests include Renal Diseases and Glomerulopathies, Chronic Kidney Disease and Diabetes, Systemic Lupus Erythematosus Research, and Vasculitis and related conditions.
h-index
89
citations
31,741
works
349
NIH funding
primary concept
email

Recent publications

Exome analysis links kidney malformations to developmental disorders and reveals causal genes
Nature Communications 2025cited by 9position: middledoi
A meta-analysis of albuminuria as a surrogate endpoint for kidney failure
Nature Medicine 2025cited by 8position: middledoi
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
The Lancet 2023cited by 251position: middledoi
Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy
Nature Genetics 2023cited by 166position: middledoi
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Nature Medicine 2023cited by 144position: middledoi
Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification
Kidney International 2023cited by 106position: middledoi
Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease
Nature Communications 2023cited by 65position: middledoi
Mayo Clinic Consensus Report on Membranous Nephropathy: Proposal for a Novel Classification
Mayo Clinic Proceedings 2023cited by 43position: middledoi
Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD
Journal of the American Society of Nephrology 2023cited by 23position: middledoi
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD
Clinical Journal of the American Society of Nephrology 2023cited by 18position: middledoi
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria
Kidney International Reports 2022cited by 89position: lastdoi
Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis
Kidney International 2022cited by 87position: middledoi
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
American Journal of Nephrology 2022cited by 59position: middledoi
Effects of Bardoxolone Methyl in Alport Syndrome
Clinical Journal of the American Society of Nephrology 2022cited by 46position: middledoi
Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
American Journal of Nephrology 2022cited by 22position: middledoi
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis
American Journal of Kidney Diseases 2021cited by 92position: middledoi
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome
American Journal of Nephrology 2021cited by 47position: middledoi
Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
American Journal of Kidney Diseases 2021cited by 19position: middledoi
The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis
Nature Communications 2020cited by 218position: middledoi
Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study
Kidney International Reports 2020cited by 26position: middledoi
Clinical trial recommendations for potential Alport syndrome therapies
Kidney International 2020cited by 14position: middledoi
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
New England Journal of Medicine 2019cited by 584position: middledoi
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
The Lancet Diabetes & Endocrinology 2019cited by 364position: middledoi
Health-related quality of life in glomerular disease
Kidney International 2019cited by 59position: middledoi
Contributions of Rare Gene Variants to Familial and Sporadic FSGS
Journal of the American Society of Nephrology 2019cited by 57position: middledoi
The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network
Clinical Kidney Journal 2019cited by 20position: middledoi
Whole-Exome Sequencing in Adults With Chronic Kidney Disease
Annals of Internal Medicine 2018cited by 203position: middledoi
An eQTL Landscape of Kidney Tissue in Human Nephrotic Syndrome
The American Journal of Human Genetics 2018cited by 184position: middledoi
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease
American Journal of Kidney Diseases 2018cited by 134position: middledoi
Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study
Kidney International Reports 2018cited by 78position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Lesley A. Inker · Boston University7 papers (2016–2025) · 5 papers (2016–2025)Bart Maes · AZ Delta5 papers (2016–2025) · 5 papers (2016–2025)Jürgen Floege · University of Hong Kong4 papers (2021–2025)Philip Kam‐Tao Li · Hospital Authority4 papers (2021–2025)Pietro A. Canetta · Columbia University Irving Medical Center4 papers (2012–2016)Tom Greene · University of Utah4 papers (2016–2023)Andrew S. Bomback · Columbia University Irving Medical Center4 papers (2012–2022)Giuseppe Remuzzi · Mario Negri Institute for Pharmacological Research4 papers (2022–2025)Hiddo J.L. Heerspink · Kidney Associates4 papers (2021–2025)Willem Collier · University of Southern California3 papers (2023–2025)Howard Trachtman · New York University3 papers (2016–2022)Angie Goldsberry · Reata Pharmaceuticals (United States)3 papers (2018–2022)Christoph Wanner · Smart Material (Germany)3 papers (2023–2025)Glenn M. Chertow · Center for Clinical Research (United States)3 papers (2018–2022)Pablo E. Pérgola · Renal Associates P. A.3 papers (2018–2022)Melanie Chin · BioClinica (United States)3 papers (2018–2022)Manuel Praga · Comunidad de Madrid3 papers (2016–2023)Arnold L. Silva · Boise Kidney & Hypertension Institute3 papers (2018–2022)